Navigating the landscape of psoriasis therapy : novel targeted pathways and emerging trends
INTRODUCTION: Psoriasis is a chronic, inflammatory, non-communicable skin disorder that affects a patient's social and emotional well-being. It is characterized by hyperproliferation of keratinocytes, irregular shedding of skin cells, and abnormal invasion of inflammatory mediators. The treatment strategy is designed based on the severity of the disease condition starting from topical, phototherapy, systemic, and biologics. In recent years, extensive research into the underlying mechanisms of psoriasis has led to significant advancement in treatment options from small molecules to biologics.
AREA COVERED: This review focuses on intracellular and molecular mechanisms such as AhR, A3AR, RIP1, CGRP, and S1P that serve as novel pharmacological targets for psoriasis. Moreover, new molecules are approved or are under clinical investigation to interfere with these target mechanisms.
EXPERT OPINION: A detailed understanding of signaling pathways provides potential targets and molecular mechanisms for the inflammatory cascade in psoriasis. This has led to the development of small molecules targeting specific pathways. Further, the combination of nanotechnology can assist in dose reduction leading to reduced adverse effects in the management of psoriasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Expert opinion on therapeutic targets - 27(2023), 12 vom: 15. Juli, Seite 1247-1256 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Innani, Srinath [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adenosine A3 receptor |
|---|
| Anmerkungen: |
Date Completed 01.01.2024 Date Revised 23.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728222.2023.2288273 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364885335 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364885335 | ||
| 003 | DE-627 | ||
| 005 | 20240123231930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728222.2023.2288273 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM364885335 | ||
| 035 | |a (NLM)37997278 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Innani, Srinath |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Navigating the landscape of psoriasis therapy |b novel targeted pathways and emerging trends |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Psoriasis is a chronic, inflammatory, non-communicable skin disorder that affects a patient's social and emotional well-being. It is characterized by hyperproliferation of keratinocytes, irregular shedding of skin cells, and abnormal invasion of inflammatory mediators. The treatment strategy is designed based on the severity of the disease condition starting from topical, phototherapy, systemic, and biologics. In recent years, extensive research into the underlying mechanisms of psoriasis has led to significant advancement in treatment options from small molecules to biologics | ||
| 520 | |a AREA COVERED: This review focuses on intracellular and molecular mechanisms such as AhR, A3AR, RIP1, CGRP, and S1P that serve as novel pharmacological targets for psoriasis. Moreover, new molecules are approved or are under clinical investigation to interfere with these target mechanisms | ||
| 520 | |a EXPERT OPINION: A detailed understanding of signaling pathways provides potential targets and molecular mechanisms for the inflammatory cascade in psoriasis. This has led to the development of small molecules targeting specific pathways. Further, the combination of nanotechnology can assist in dose reduction leading to reduced adverse effects in the management of psoriasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adenosine A3 receptor | |
| 650 | 4 | |a aryl hydrogen receptor pathway (AhR) | |
| 650 | 4 | |a molecular targets | |
| 650 | 4 | |a psoriasis | |
| 650 | 4 | |a sphingosine 1 phosphate (S1P) | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Tomar, Yashika |e verfasserin |4 aut | |
| 700 | 1 | |a Rana, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Singhvi, Gautam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on therapeutic targets |d 2001 |g 27(2023), 12 vom: 15. Juli, Seite 1247-1256 |w (DE-627)NLM117849634 |x 1744-7631 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:12 |g day:15 |g month:07 |g pages:1247-1256 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728222.2023.2288273 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 12 |b 15 |c 07 |h 1247-1256 | ||